Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DYZA20
|
|||
| Drug Name |
MORF-057
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 2 | [1] | |
| Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [1] | ||
| Company |
Morphic Therapeutic Waltham, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Integrin alpha-4/beta-7 (ITGA4/B7) | Target Info | Antagonist | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05291689) A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-1). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.